Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01466049 · ClinicalTrials.gov registry record
New Biomarkers Evaluating Ovarian Cancer
A clinical trial, sponsored by Fujirebio Diagnostics.
- Completed
- Registry status
- 280
- Enrollment target
NCT01466049: Completed study, sponsored by Fujirebio Diagnostics.
NCT01466049 is a clinical trial that has completed, run by Fujirebio Diagnostics. The registered enrollment target is 280 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01466049 has completed, sponsored by Fujirebio Diagnostics.
- COMPLETED
- Registry status
- 280 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate new biomarkers for patients presenting to a physician for surgery to remove a mass in their pelvis and to continue to evaluate these types of patients using the ROMA algorithm for post-market benefits.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-03 |
What the finished NCT01466049 record still lists
NCT01466049 is an observational study that tracks outcomes without assigning an intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01466049 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01466049 about?
NCT01466049 is a clinical study titled "New Biomarkers Evaluating Ovarian Cancer". The purpose of this study is to evaluate new biomarkers for patients presenting to a physician for surgery to remove a mass in their pelvis and to continue to evaluate these types of patients using the ROMA algorithm for post-market benefits.
What is the current status of trial NCT01466049?
This trial is currently completed. The enrollment target is 280 participants. The study started on 2011-12. Estimated completion is 2014-03.
Who is sponsoring clinical trial NCT01466049?
This trial is sponsored by Fujirebio Diagnostics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia